Drug name
Last update: Jul 2026Ulonivirine (MK-8507)
Developer(s)
Drug information
MK-8507
Not provided
Small molecule
NNRTI
MK-8507, also known as Ulonivirine, is a selective, potent and novel non-nucleoside reverse transcriptase inhibitor (NNRTI) currently in clinical development for the treatment of HIV-1. MK-8507 inhibits HIV-1 allosterically through the classic NNTRI binding location adjacent to the polymerase active site. Preclinical research indicates that MK-8507 displays activity against the most common resistance mutations associated with NNRTIs (e.g. Y181C and K103N) and possesses strong antiviral effects. The pharmacokinetics of MK-8507 support once-weekly oral administration.
Ulonivirine (previously known as MK 8507) is an orally-administered investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by MSD for the treatment of HIV-1 infection. It is not approved yet.
Ulonivirine is not approved yet.
Therapeutic area(s)
- HIV
- Pre-Exposure Prophylaxis (PrEP)
- Treatment
- Prevention
Administration route
Oral
Associated long-acting platforms
Oral solid form
Use of drug
- Self-administered
- Weekly
Dosage
Not provided
Not provided
Not provided
Not provided
Not provided
Associated compounds, formulations and regimens
MK-8591B (islatravir + ulonivirine)
Associated technologies
Not provided
Additional information
Developer(s)
Merck / MSD
Merck & Co., Inc. is an American multinational pharmaceutical company known as Merck Sharp & Drone (MSD) in territories outside of the USA and Canada. Merck was originally established in 1891, and is currently headquartered in Rahway, New Jersey. The company is particularly well known for developing and manufacturing biologic therapies, vaccines, medicines and animal health products.
Drug structure
Scale-up and manufacturing prospects
Unknown
Unknown
Unknown
Unknown
Excipients & delivery device(s)
Not provided
Not provided
Not provided
No delivery device
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided